Cutaneous melanoma represents a significant and growing global health burden, with marked geographic, demographic, and temporal variation. This review synthesizes current epidemiological evidence on incidence, mortality, temporal trends, etiology, and disease burden, drawing on data from international cancer registries, the Global Burden of Disease (GBD) consortium, and recent epidemiological studies spanning approximately 2015–2025.
Incidence and Prevalence: Regional Patterns
Global melanoma incidence demonstrates striking geographic heterogeneity, closely correlated with latitude, ancestry, and sociodemographic development. According to GLOBOCAN 2022 data, an estimated 331,722 new melanoma cases occurred worldwide, yielding a global age-standardized incidence rate (ASIR) of 3.20 per 100,000 population 7. However, this aggregate conceals profound regional disparities.
High-incidence regions include Oceania (ASIR 29.80 per 100,000), Northern America (ASIR 16.30), and Europe (ASIR 10.40) 7. Country-specific rates reveal even greater extremes: Australia (37.0 per 100,000), New Zealand (35.8), Denmark (31.1), and Norway (30.6) report the world's highest incidence 743. In absolute terms, Australia and New Zealand exhibit cumulative lifetime risks of approximately 3.75%, with Australia's lifetime risk having tripled from 1 in 46 (1982) to an estimated 1 in 15 (2020) 443.
In contrast, low-incidence regions include Asia (ASIR 0.41 per 100,000) and Africa (ASIR 0.90) 7. Specific countries demonstrate markedly lower rates: China (0.6 per 100,000), India (0.2), Japan (1–2 per 100,000), and several sub-Saharan African nations 4344. This geographic gradient reflects differences in constitutive skin pigmentation, ambient UV exposure, and population screening practices.
United States epidemiology (2018–2022 data) shows an overall ASIR of 21.9 per 100,000 with substantial sex disparity: males 27.8 per 100,000 versus females 17.5 per 100,000 1. Racial/ethnic stratification reveals profound disparities, with non-Hispanic White individuals bearing the highest burden (males 39.7, females 26.8 per 100,000), followed by American Indian/Alaska Native (males 11.6, females 7.5), Hispanic (4.7 for both sexes), and Asian/Pacific Islander and Black populations (<1.3 per 100,000) 1. The 2025 projection estimates approximately 105,000 new invasive melanoma cases in the United States alone 5.
Europe exhibits variable incidence across member states. Western Europe reports an ASIR of 14.55 per 100,000, with country-level variation: Switzerland (20.3), Netherlands (19.4), United Kingdom (14.6), Germany and Italy (11.4 each), France (10.2), and Spain (6.9) 43. Nordic countries consistently rank among the highest globally (Denmark 31.1, Norway 30.6, Sweden 18.0) 43.
Latin America shows substantially lower incidence: Brazil (2.8), Argentina (2.9), and Mexico (1.8 per 100,000) 43. Limited registry data exist for Middle East/North Africa and Sub-Saharan Africa, though available evidence suggests rates <1.0 per 100,000 in most populations 7.
Age, Sex, and Stage Distribution
Melanoma incidence increases markedly with age, peaking in individuals aged 65–74 years (27.4% of US cases) with a median age at diagnosis of 66 years 1. Males consistently demonstrate 1.3–1.4-fold higher incidence than females across most regions, except in Africa where females show slightly elevated rates 7. Age-specific patterns reveal that melanoma remains relatively rare below age 20 (<0.3% of US cases) but rises substantially thereafter 1.
Stage at diagnosis critically determines prognosis. US SEER data (2015–2021) indicate that 77% of melanomas are diagnosed at localized stage (5-year survival 100.0%), 10% at regional stage (75.7% survival), and 5% with distant metastases (34.6% survival) 1. This predominantly early-stage distribution reflects intensive opportunistic screening in high-incidence populations, though it raises concerns about potential overdiagnosis of indolent lesions 47.
Melanoma Subtypes in Non-White Populations
Japan presents a distinct epidemiological profile, with acral lentiginous melanoma (ALM) representing 40.8% of all melanomas—the most prevalent subtype—contrasting sharply with Western populations where superficial spreading melanoma predominates 44. Japanese melanoma patients also exhibit lower BRAF mutation rates overall (27.2%), with ALM showing particularly low BRAF V600E frequency (8.5%) 44. This subtype distribution underscores the importance of examining palmar, plantar, and subungual sites during clinical examination of Asian, African, and Hispanic patients, in whom ALM represents a disproportionate share of melanoma burden.
Temporal Trends (2015–2025)
Global melanoma incidence has continued its decades-long upward trajectory, though with notable regional heterogeneity and recent stabilization in younger cohorts. GBD 2019 analysis (1990–2019) documented a global ASIR increase with an estimated annual percentage change (EAPC) of +1.13% (95% CI: 0.93–1.32) 6. Updated GBD 2021 data showed minimal growth from 2.98 per 100,000 (1990) to 3.56 per 100,000 (2021), yielding an EAPC of +0.65%—the lowest among all skin cancer subtypes 16.
United States trends (joinpoint analysis 2013–2022) reveal continued incidence growth at +1.2% per year, while mortality rates declined at −2.8% per year (2014–2023) 12. Critically, age-stratified analyses demonstrate divergent patterns: older adults (≥65 years) show persistent incidence increases (+2.5% annually), whereas younger cohorts exhibit stabilization or decline. Among individuals aged 15–39 years, incidence declined at −1.2% per year, and in those <20 years, rates fell dramatically (−5.5% annually, 2013–2022) 2.
Sweden (1990–2022 cohort of 34,800 cases aged <60 years) similarly documented peak incidence in ages 20–49 around 2013–2015, followed by stable or significantly declining rates through 2022 3. Mortality among ages 30–59 declined significantly during this period 3.
Regional variation in temporal trends (1998–2012 GLOBOCAN data) showed statistically significant incidence increases across all continents: European males (AAPC +5.25%), European females (+4.01%), Asian males (+2.91%), Asian females (+2.03%), American males (+2.71%), and American females (+2.63%) 7. East Asia demonstrated the steepest increase (EAPC +3.28%), with South Korea exhibiting the greatest national-level rise (EAPC +5.87%) 6.
The divergence between rising incidence and declining mortality likely reflects multiple factors: earlier detection through opportunistic screening, stage migration toward localized disease, therapeutic advances (particularly immune checkpoint inhibitors and BRAF/MEK inhibitors post-2011), and potential overdiagnosis of biologically indolent melanomas 1616.
Etiology and Risk Factors
Ultraviolet Radiation Exposure
UV radiation remains the predominant modifiable risk factor for cutaneous melanoma. A systematic review (2002–2021) of 26 studies encompassing 3,417 melanoma cases identified sunburn as the most consistently associated exposure, with pooled adjusted odds ratio (OR) of 1.23 (95% CI: 1.04–1.46) and unadjusted OR of 1.66 (95% CI: 1.40–1.97) 24. Individual study ORs ranged from 1.23 to 8.48, underscoring the strength and consistency of this association. Cumulative sun exposure demonstrated ORs ranging from 1.1 to 5.2 across studies 24.
Indoor tanning represents a distinct high-UVA exposure source. Systematic reviews document that modern tanning devices emit substantially higher UVA irradiances than natural summer sun, with concerning implications given UVA's carcinogenic properties and minimal photoprotective benefit 33. Approximately 30% of white female US high school students report indoor tanning use, with 25% reporting >20 annual sessions 50. Indoor tanning is particularly prevalent among young non-Hispanic white females, contributing to elevated melanoma risk in this demographic 30.
Childhood UV exposure shows complex epidemiological patterns. A Women's Health Initiative cohort (56,557 postmenopausal women, 11.9-year follow-up) found that residential UV exposure in adulthood—not childhood—drove non-melanoma skin cancer risk (OR 1.21), while melanoma risk showed no significant association with either childhood or adulthood residential UV 35. However, childhood sunburn remains a robust melanoma risk factor, potentially mediated by nevus induction 28.
Phenotypic Risk Factors
Fair skin (Fitzpatrick phototypes I–II), red or blonde hair, blue or green eyes, freckling, and high nevus burden consistently predict melanoma risk 31. A Spanish university cohort (n=535, ages 18–25) documented mean common melanocytic nevus counts of 94.28, with atypical nevi significantly elevated in individuals with low phototypes and family history of skin cancer 25. Sunburn in the preceding summer affected 88.2% of participants, yet only 24.2% used SPF ≥15 sunscreen 25.
In pediatric populations, a cross-sectional analysis of 443 children demonstrated that sun exposure increased log nevi counts among children without sunburn (p<0.001), but not among those with sunburn (p=0.14), suggesting complex gene-environment interactions 28. Children with high sun sensitivity and sunburn history exhibited elevated nevus counts independent of sun exposure level 28.
Genetic Predisposition
CDKN2A represents the predominant melanoma susceptibility gene. A prospective study of 333 patients with multiple or familial melanomas (2021–2024) identified pathogenic/likely pathogenic germline variants in 4.3% of tested individuals, predominantly in CDKN2A 39. MC1R variants contribute to melanoma risk through reduced melanin production and impaired DNA repair capacity, particularly in fair-skinned populations 7.
Gene-environment interactions demonstrate risk modification. A case-control study (177 melanoma patients, 148 controls) found that individuals with GSTM1 null genotype exposed to household pesticides ≥2 times/year exhibited 2.76-fold increased melanoma risk (95% CI: 1.08–7.08) compared to GSTM1-active individuals with low exposure 37. Duration of exposure ≥10 years in GSTM1 null individuals conferred OR 2.78 (95% CI: 1.01–7.66) 37.
BRAF mutations show geographic and subtype variation. Overall BRAF mutation prevalence in Western melanoma cohorts approximates 40–50%, though Japanese data reveal substantially lower rates (27.2% overall, 8.5% in ALM, 4.8% in mucosal melanoma) 44.
Host Immunosuppression
Solid organ transplant recipients and HIV-infected individuals experience elevated melanoma risk, though quantitative estimates were not available in the retrieved materials. Southern Sub-Saharan Africa's high burden of HIV/AIDS contributes to elevated squamous cell carcinoma mortality and DALYs, though melanoma-specific immunosuppression data remain limited 6.
Disease Burden: Mortality, DALYs, and Quality of Life
Global melanoma mortality in 2019 totaled 62,844 deaths (95% UI: 46,294–71,033), with an age-standardized mortality rate (ASMR) of approximately 0.53 per 100,000 67. GLOBOCAN 2022 estimated 58,667 deaths globally, consistent with declining or stable mortality trends 7. Regional mortality variation mirrors incidence patterns: New Zealand reports the highest ASMR (3.90 per 100,000), followed by European countries (1.50) and Northern America (1.10), versus Africa (0.37) and Asia (0.21) 7.
United States mortality (2019–2023) averaged 2.0 per 100,000, with substantial racial/ethnic disparities: non-Hispanic White males (3.8), non-Hispanic White females (1.7), versus Black, Asian/Pacific Islander, and Hispanic populations (<0.8) 1. The 2025 projection estimates 8,430 melanoma deaths in the United States 5.
Temporal mortality trends show encouraging declines in high-income countries. Global ASMR declined with EAPC −0.27% (95% CI: −0.36 to −0.19) from 1990–2019 6. US mortality fell 2.8% annually (2014–2023) despite rising incidence 1. Sweden documented significant mortality reductions in ages 30–59 years, though not in those ≥60 3.
Disability-Adjusted Life Years (DALYs)
GBD 2019 estimated 1.71 million melanoma DALYs globally (95% UI: 1.26–2.00 million), with years of life lost (YLL) accounting for the majority of burden 6. Age-standardized DALY rates (ASDR) declined from 24.33 per 100,000 (1990) to 19.63 per 100,000 (2021), with EAPC −0.67% 16. Australasia bore the highest regional DALY burden (ASDR 109.97 per 100,000 in 2021) 16.
A Belgian Cancer Registry disease-transition modeling analysis (2009–2011 cohort, n=8,016) provided granular stage-specific burden estimates: total melanoma burden averaged 3.67 DALYs per case or 90.81 per 100,000 inhabitants, with YLL comprising 80.4% of total DALYs 17. Stage-specific YLL contribution at diagnosis: Stage I (27.8%), Stage II (32.7%), Stage III (26.2%), and Stage IV (13.3%) 17. Years lived with disability (YLD) were predominantly generated by node metastatic melanoma (52.6% of total YLD), followed by localized disease (34.8%) and distant metastases (12.6%) 17.
Pediatric melanoma (age <20 years) exhibited age-standardized incidence of 0.13 per 100,000, mortality of 0.02 per 100,000, and DALY rate of 1.46 per 100,000 in 2019, with declining mortality (EAPC −0.62%) and DALYs (EAPC −0.58%) from 1990–2010 13.
Quality of Life and Treatment Toxicity
The CheckMate 067 phase III trial (803 advanced melanoma patients) assessed health-related quality of life (HRQoL) with immune checkpoint inhibitors 48. Nivolumab monotherapy and nivolumab plus ipilimumab combination both maintained HRQoL with no clinically meaningful deterioration over 79 weeks compared with ipilimumab, measured by EORTC QLQ-C30 and EQ-5D instruments 48. Notably, despite combination therapy producing substantially higher grade 3/4 adverse events (58.5%) versus nivolumab monotherapy (20.8%), these toxicity differences did not translate into clinically meaningful HRQoL decrement 48. Among patients discontinuing due to adverse events, only the combination arm showed clinically meaningful EQ-5D decline 48.
Disparities and Access
Profound racial, ethnic, and socioeconomic disparities characterize melanoma epidemiology. US incidence in non-Hispanic White males (39.7 per 100,000) exceeds that in Black males (1.0) by nearly 40-fold 1. However, mortality disparities are less extreme but clinically significant: non-Hispanic White male mortality (3.8) versus Black male mortality (0.4) represents a 9.5-fold difference, suggesting later-stage presentation and/or differential treatment access in minority populations 1.
Socioeconomic status associates with melanoma stage at presentation, with systematic reviews identifying lower SES as a modifier of diagnostic delay and advanced-stage disease 27. Geographic access to dermatology care, screening practices, and health insurance coverage contribute to these disparities. Italy's north-south comparison (Emilia-Romagna vs. Sicily, 2008–2017) revealed northern regions' standardized rate ratios of 5.31 for in situ melanoma and 3.58 for thin invasive melanoma coexisting with 3.00–5.25-fold higher dermatologic surveillance intensity 14.
Prevention, Screening, and Overdiagnosis
Primary prevention through sun safety education shows measurable efficacy. A systematic review of 66 pediatric intervention studies (2015–2025) documented positive behavioral changes in 73% of studies, including increased sunscreen use, protective clothing, and shade-seeking 46. However, behavioral sustainability remains challenging 46.
Indoor tanning legislation has proliferated across US states and internationally, though enforcement variability limits real-world impact 495152. California's 2011 minor tanning ban catalyzed significantly increased media coverage of tanning risks (58% of post-ban articles versus 30% pre-ban mentioned indoor tanning risks, p<0.05) 49.
Screening effectiveness and overdiagnosis present complex tradeoffs. An Australian prospective cohort (43,762 residents, 2015–2017) found that individuals with prior physician skin examination demonstrated 29% higher melanoma incidence (aHR 1.29, 95% CI: 1.02–1.63) and 85% higher biopsy rates (aHR 1.85) versus unscreened participants 47. Critically, the excess detection comprised predominantly in situ melanomas (aHR 1.45) rather than invasive disease (aHR 1.05), with similar Breslow thickness distributions between screened and unscreened groups 47. The absolute 5-year risk difference of 0.5% translates to a number needed to screen of approximately 206 to detect one excess (predominantly indolent) melanoma 47.
Data Sources, Methods, and Limitations
This review synthesizes data from IARC GLOBOCAN (2022 estimates) 7, IHME Global Burden of Disease (2019, 2021 datasets) 616, US SEER registries (2018–2022 incidence, 2015–2021 survival) 12, national cancer registries (Sweden, Japan, Australia, Ecuador, Lithuania, Iceland, Italy) 34910111444, and peer-reviewed epidemiological studies. Age-standardization employed WHO or Segi world standard populations as specified by source registries.
Critical limitations include: (1) registry completeness heterogeneity, particularly in low- and middle-income countries; (2) evolving AJCC staging (7th vs. 8th edition transitions affect stage distribution comparability); (3) diagnostic intensity variation (dermoscopy adoption, screening program heterogeneity) contributing to potential overdiagnosis in high-resource settings; (4) ICD-10 C43 coding practices that may inconsistently exclude uveal/mucosal melanomas; (5) limited granular data for Middle East, North Africa, and Sub-Saharan Africa; and (6) rapidly evolving treatment landscape (immune checkpoint inhibitors, targeted therapies post-2011) complicating mortality trend interpretation.
Data gaps persist for acral lentiginous melanoma-specific incidence in Asian, African, and Hispanic populations; comprehensive economic burden estimates; patient-reported outcomes by stage and treatment modality; and penetrance estimates for CDKN2A/BAP1 germline mutations in population-based cohorts.
Conclusion
Cutaneous melanoma incidence continues to rise globally (ASIR 3.20–3.56 per 100,000) with profound geographic variation (Australia 37.0 versus China 0.6 per 100,000), driven by UV exposure, fair skin phenotype, genetic susceptibility, and screening intensity. Encouragingly, mortality has declined in high-income countries (US −2.8%/year) despite incidence growth, reflecting earlier detection and therapeutic advances. Disease burden remains substantial (1.71 million DALYs globally), with YLL dominating and regional disparities mirroring incidence patterns. Prevention through UV avoidance, sun safety education, and tanning bed regulation offers primary prevention opportunities, though screening programs risk overdiagnosis of indolent lesions. Addressing racial/ethnic and socioeconomic disparities in early detection and treatment access remains a critical public health priority.